NantBioRenewables launches brand transformation
The strategic rebrand includes a modernised corporate identity, advanced digital platform, and an integrated marketing system, to support the rapid growth of the company.
The transformation encompasses all aspects of the customer experience, from the first digital interaction to sales involvement and continuous support for partnerships.
Central to NantBioRenewables' differentiation is its proprietary Ocean Calcium Sand (OCS) technology, touted to be the 'world's first carbon-negative raw material for compostable packaging'.
This material not only removes CO₂ from the atmosphere but also offers superior mechanical properties and industrial compostability, stated the company.
NantBioRenewables Global Sales & Marketing director Lila Karlsen McNutt said: "This investment in our brand infrastructure demonstrates our commitment to long-term growth and customer success.
"As we scale our revolutionary Ocean Calcium Sand technology globally, our customers deserve marketing and sales tools that reflect the premium nature of our innovations."
The company manufactures a range of products in the US, including straws, tableware, cutlery, and thermoformed packaging solutions for various sectors.
The brand transformation is a key part of NantBioRenewables' aggressive growth strategy, enhancing digital capabilities for lead generation and customer engagement.
NantBioRenewables chief operating officer Kenn Budlong said: "Our brand transformation ensures that our marketing and sales capabilities match the revolutionary nature of our technology.
"When customers experience our new brand touchpoints, they immediately understand they're engaging with a premium innovation leader, not just another packaging supplier."
The transformation is expected to accelerate deal closure and customer onboarding, positioning the company to capitalise on the sustainable packaging market's projected growth to $440bn by 2030.
NantBioRenewables has assembled an experienced sales and marketing team with expertise in the sustainable packaging industry to complement the brand transformation.
With its unique combination of carbon-negative raw materials and proven compostability, NantBioRenewables will create significant competitive advantages in this expanding market, the company said.
"NantBioRenewables launches brand transformation" was originally created and published by Packaging Gateway, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
18 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
